BACKGROUND: The aim of this study was to clarify the potential advantages of a low-dose regimen of trimethoprim-sulfamethoxazole prophylaxis to prevent Pneumocystis jirovecii pneumonia (PJP) in transplant recipients (80/400 mg/d every day or 160/800 mg/d every other day) with those obtained from the full-dose prophylaxis (160/800 mg/d every day) or no prophylaxis. METHODS: Prospectively randomized and retrospectively case controlled studies were selected. RESULTS: Four studies matched the inclusion criteria-2 randomized and 2 case controls-for a total of 570 patients. The pneumonia incidence was 0% after full-dose prophylaxis (0/181), 1% after the low-dose regimen (1/105), and 11% with no prophylaxis (31/284). Pneumonia occurrences were significant lower between the full-dose prophylaxis versus the no prophylaxis group (0% vs 11%; P < .001), and between the low-dose and no prophylaxis groups (1% vs 11%; P < .001). There was no difference between patients receiving the full-dose prophylaxis versus the low-dose regimen (0% vs 1%; P = NS). CONCLUSIONS: The low-dose gives similar results as the full-dose regimen for the prevention of PJP and seems a feasible, safe option for transplanted patients.
BACKGROUND: The aim of this study was to clarify the potential advantages of a low-dose regimen of trimethoprim-sulfamethoxazole prophylaxis to prevent Pneumocystis jirovecii pneumonia (PJP) in transplant recipients (80/400 mg/d every day or 160/800 mg/d every other day) with those obtained from the full-dose prophylaxis (160/800 mg/d every day) or no prophylaxis. METHODS: Prospectively randomized and retrospectively case controlled studies were selected. RESULTS: Four studies matched the inclusion criteria-2 randomized and 2 case controls-for a total of 570 patients. The pneumonia incidence was 0% after full-dose prophylaxis (0/181), 1% after the low-dose regimen (1/105), and 11% with no prophylaxis (31/284). Pneumonia occurrences were significant lower between the full-dose prophylaxis versus the no prophylaxis group (0% vs 11%; P < .001), and between the low-dose and no prophylaxis groups (1% vs 11%; P < .001). There was no difference between patients receiving the full-dose prophylaxis versus the low-dose regimen (0% vs 1%; P = NS). CONCLUSIONS: The low-dose gives similar results as the full-dose regimen for the prevention of PJP and seems a feasible, safe option for transplanted patients.
Authors: Jonathan Ling; Tara Anderson; Sanchia Warren; Geoffrey Kirkland; Matthew Jose; Richard Yu; Steven Yew; Samantha Mcfadyen; Alison Graver; William Johnson; Lisa Jeffs Journal: Clin Kidney J Date: 2017-06-23
Authors: Annika Y Classen; Larissa Henze; Marie von Lilienfeld-Toal; Georg Maschmeyer; Michael Sandherr; Luisa Durán Graeff; Nael Alakel; Maximilian Christopeit; Stefan W Krause; Karin Mayer; Silke Neumann; Oliver A Cornely; Olaf Penack; Florian Weißinger; Hans-Heinrich Wolf; Jörg Janne Vehreschild Journal: Ann Hematol Date: 2021-04-13 Impact factor: 3.673
Authors: Abdul Haseeb; Mohammed A S Abourehab; Wesam Abdulghani Almalki; Abdulrahman Mohammed Almontashri; Sultan Ahmed Bajawi; Anas Mohammed Aljoaid; Bahni Mohammed Alsahabi; Manal Algethamy; Abdullmoin AlQarni; Muhammad Shahid Iqbal; Alaa Mutlaq; Saleh Alghamdi; Mahmoud E Elrggal; Zikria Saleem; Rozan Mohammad Radwan; Ahmad Jamal Mahrous; Hani Saleh Faidah Journal: Int J Environ Res Public Health Date: 2022-02-28 Impact factor: 3.390